SOHO Italy 2022 | The possibility of using MRD status to drive treatment in AML
Alessandro Isidori
• 24 Oct 2022
Alessandro Isidori, MD, PhD, Marche Nord Hospital, Pesaro, Italy, discusses the possible implications for measurable residual disease (MRD)-driven therapy in younger patients with acute myeloid leukemia (AML). Dr Isidori first explains that MRD is a strong predictor of outcome in patients with AML, and further reflects on the need for more trials in this space. This interview took place at The 4th Society of Hematologic Oncology (SOHO) Italy Annual Conference, held in Rome, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
